In conclusion, we isolated a new EMT model from HNSCC line with gefitinib resistance and demonstrated that EMT as well as gefitinib resistance is mediated by the downregulation of membrane EGFR through compensatory activation of Akt/GSK-3β/snail pathway. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.